0001636282-26-000087.txt : 20260702 0001636282-26-000087.hdr.sgml : 20260702 20260702213302 ACCESSION NUMBER: 0001636282-26-000087 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260701 FILED AS OF DATE: 20260702 DATE AS OF CHANGE: 20260702 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sloan Sheldon CENTRAL INDEX KEY: 0002038798 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37722 FILM NUMBER: 261153962 MAIL ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Spyre Therapeutics, Inc. CENTRAL INDEX KEY: 0001636282 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 464312787 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 6176515940 MAIL ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: Aeglea BioTherapeutics, Inc. DATE OF NAME CHANGE: 20150311 4 1 wk-form4_1783042377.xml FORM 4 X0609 4 2026-07-01 0 0001636282 Spyre Therapeutics, Inc. SYRE 0002038798 Sloan Sheldon false 221 CRESCENT STREET, BUILDING 23 SUITE 105 WALTHAM MA 02453 0 1 0 0 Chief Medical Officer 1 Common Stock 2026-07-01 4 M 0 8334 27.46 A 8334 D Common Stock 2026-07-01 4 S 0 6500 87.52 D 1834 D Common Stock 2026-07-01 4 S 0 1834 88.34 D 0 D Stock Option (Right to Buy) 27.46 2026-07-01 4 M 0 8334 0 D 2034-10-01 Common Stock 8334 305000 D This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.03 to $87.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.03 to $88.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. /s/ Heidy King-Jones, as Attorney-in-Fact 2026-07-02